

IN THE DRAWINGS:

Replacement drawing sheets for Figures 5 and 6 are being submitted concurrently herewith in compliance with 37 C.F.R. § 1.123. Please replace the originally submitted drawing sheets entitled "Figure 5," "Figure 5 (continued)," "Figure 6," and "Figure 6 (continued)," with replacement drawing sheets entitled "Figures 5a," "Figure 5b," "Figure 6a," and "Figure 6b," respectively.

REMARKS / ARGUMENTS

RESPONSE TO NOTICE TO COMPLY

The Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice") mailed October 17, 2006, has been received and reviewed. The Notice alleges that the application failed to comply with the sequence listing rules under 37 C.F.R. § 1.821 – 1.825, because nucleotide sequences appearing in the drawings (e.g., Figures 5 and 6) were not identified by a sequence identifier in accordance with 37 C.F.R. § 1.821(d). The Notice further states: "Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers."

In order to bring the application in compliance with the sequence listing rules under 37 C.F.R. § 1.821 – 1.825, Applicant submits replacement drawing sheets for Figures 5 and 6, in compliance with 37 C.F.R. § 1.123, herewith. In compliance with 37 C.F.R. § 1.821(d), every sequence in the replacement drawing sheets is now accompanied by a "SEQ ID NO:_" sequence identifier. Entry of the replacement drawing sheets, which have been amended as required, is respectfully requested.

Further, the nucleotide sequences appearing in Figures 5 and 6, which are now accompanied by a "SEQ ID NO:_" sequence identifier, have been added to the previously filed Sequence Listing, to create an Amended Sequence Listing submitted herewith under separate cover. Because the nucleotide sequences appearing in the replacement drawing sheets are identical to those in the originally filed Figures 5 and 6, the amendments made to the Sequence Listing do not constitute new matter. Consequently, entry of the Amended Sequence Listing provided herewith on compact disks into the application is respectfully requested. Further, an amendment to the specification has been provided above, in order to incorporate by reference the Amended Sequence Listing being supplied on compact disk into the application. Entry of this amendment to the specification is also respectfully requested.

AMENDMENTS TO THE CLAIMS

In an effort to streamline and expedite examination of the application on the merits, Applicants have cancelled all pending claims (claims 1-19), and added new claims 20 through 27. These eight new claims substantially correspond to the group of claims previously elected by the Applicants in their Response to the Restriction Requirement, which was issued in the Office Action mailed June 21, 2006.

Support for these new claims can be found throughout the specification. However, specific support for the fact that the UEV domain of the Tsg101 protein and the PTAP motif of the late domain of HIV GAGp6 are responsible for the interactions between Tsg101 and HIV GAG is found in lines 1-2, on page 25 of the specification. Additionally, support of the assertion that antibodies that bind to the UEV domain of Tsg101 can be used to interfere with or inhibit the binding of Tsg101 and HIV GAG is found in line 18, on page 12 of the specification. Further, the definition of “selectively immunoreactive” in regard to antibodies, is provided in the last paragraph on page 17 of the specification. And finally, the fact the term “antibody,” as used in the instant specification, encompasses monoclonal antibodies, polyclonal antibodies, antibody fragments, single chain antibodies, and humanized antibodies, is found in lines 19-24 on page 17, and throughout the section of the specification entitled “3. Antibodies,” which found on pages 36 through 41.

Entry of the new claims and their examination on the merits is respectfully requested.

AMENDMENTS TO THE SPECIFICATION

Two distinct amendments to the specification are being requested herein. In the first amendment, the first paragraph of the specification in the “Cross-Reference to Related Applications” is being replaced in order to correct a grammatical error and supply missing information, as indicated. This amendment should be entered into the application, because it does not add new matter to the specification, and it serves to correct obvious defects. The second amendment seeks to add a paragraph to the application that serves to incorporate by reference the New Sequence Listing written on

compact disk, which is being provided herewith, in response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed October 17, 2006. This amendment does not add new subject matter to the specification, because the New Sequence Listing, which is provided on the compact disks, differs from the originally-filed Sequence Listing only by the incorporation of individual SEQ ID NOs:43-75, which correspond to the 33 nucleotide sequences depicted in the originally-filed Figures 5 and 6. Therefore, this amendment should be entered into the application because it does not add new matter and because the New Sequence Listing was necessitated by the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" which seeks to bring the application into compliance with the sequence listing rules under 37 C.F.R. § 1.821 – 1.825.

AMENDMENTS TO THE DRAWINGS

As noted above, Figures 5 and 6 are being amended in response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 17, 2006. Also as noted, the Figures have been amended by the addition of "SEQ ID NO:_" sequence identifiers for every nucleotide sequence that appears in these Figures 5 and 6, in order to bring the Figures into compliance with 37 C.F.R. § 1.821(d). Additionally, as noted above, the titles of the Figures have been changed from "Figure 5," "Figure 5 (continued)," "Figure 6," and "Figure 6 (continued)," to "Figure 5a," "Figure 5b," "Figure 6a," and "Figure 6b," respectively.


Replacement Sheets for Figures 5 and 6 containing these amendments have been provided herewith, and their entry into the application is respectfully requested.

CONCLUSION

It is believed that, upon entry of the amendments described above, the as-filed application will be in full compliance with 37 C.F.R. §§ 1.821 – 1.825. Should the Examiner determine that additional issues remain that might be resolved by a telephone conference, he is invited to contact the undersigned via his direct office line at 801-883-3463.

It is believed that no extension of time or additional fee is due with this response. If this is incorrect, an extension of time as deemed necessary is hereby requested, and the Commissioner is hereby authorized to charge any appropriate fees or deficiency, or credit any over payment, to Deposit Account no. **50-1627**.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Herbert L. Ley III', with a long horizontal flourish extending to the right.

Herbert L. Ley III, Ph.D.
Registration No. 53,215

Date: November 17, 2006

Intellectual Property Department
Myriad Genetics, Inc.
(Customer No. 26698)
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600
Fax: 801-883-3871